ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NBP
RNA (44) MSLE (46) SPRB (34) MENS (33) ⌘ Pro Terminal →

NovaBridge Biosciences (NBP) — RQD Stock Rating Cockpit

$1.07 -10.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.05

NovaBridge Biosciences (NBP) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $137.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NBP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NovaBridge Biosciences (NASDAQ: NBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.07 (-10.46% 1D, market cap $137.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NBP ranks #632 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NBP compare to RNA and MSLE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RNA (Atrium Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $141.5M) and MSLE (Satellos Bioscience Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $142.2M). Among the 5-stock peer group, NBP leads on earnings multiple (N/A) while MENS leads on capital efficiency (-28.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NBP?
▼

Per NBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778016), NovaBridge Biosciences generated $264.0M in revenue (+83.3% YoY), -$46.3M in net income, and $0 in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.05 (-2.07%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 1.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE NBP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NBP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY NBP SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.29+10.1% Next Q
Q2 (-2Q)
39
Grade E$1.42-12% Next Q
Q3 (-1Q)
37
Grade E$1.25-14.4% Next Q
Current
34
Grade E$1.07-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NBP currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($1.12) forces dealer call-delta covering toward $5.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
37.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.07H: $5
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NBP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (28)

8/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like NBP
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NBP)

  • ✓Walkthrough of NBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.42%▼ SUPPORT BREAKDOWN
2026-11-03O $1.21H $1.21L $1.07C $1.07VOL 583.2K
RES: $1.32SUP: $1.17SMA50: $1.48SMA200: $2.16
$3.86$3.11$2.35$1.59$0.84RES $1.32SUP $1.17$1.072026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NBP Butterfly Map → + Track NBP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +83.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NBP)

Health Care Rank #632 of 1015 ⚔️ RNA vs NBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NBP vs. RNA, MSLE, SPRB, MENS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NovaBridge Biosciences (NBP) ranks #632 by composite RQD confidence (34/100, grade E) and #614 by equity capitalization ($137.9M). Within this direct 5-issuer industry benchmark cohort, NBP leads on earnings valuation at N/A trailing P/E, while MENS leads on capital efficiency and profitability with -28.8% ROIC and — gross margin. MSLE currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NBP at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NBP ACTIVE
NovaBridge Biosciences
E 34/100 — — -35.0% -10.46% $137.9M Benchmark Subject
RNA
Atrium Therapeutics Inc.
D 44/100 — — — +3.39% $141.5M /rna-vs-nbp →
MSLE
Satellos Bioscience Inc.
D 46/100 — — — -4.48% $142.2M /msle-vs-nbp →
SPRB
Spruce Biosciences Inc.
E 34/100 — — -35.0% -3.97% $133.3M /sprb-vs-nbp →
MENS
Jyong Biotech Ltd.
E 33/100 — — -28.8% -0.53% $142.9M /mens-vs-nbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001778016 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NovaBridge Biosciences (NBP) reported GAAP revenue of $264.0M (+83.3% vs. FY2024 revenue of $144.0M , and +41664.7% cumulative change since FY2023) , GAAP net income of -$46.3M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, NBP closed FY2025 with $260.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $264.0M -$46.3M — — $260.5M —
FY2024 (FY) 2024-12-31 $144.0M -$22.2M — — $212.7M —
FY2023 (FY) 2023-12-31 $632.0K -$207.7M -$183.8M -$183.8M — —

3. NBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NovaBridge Biosciences (NASDAQ: NBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.07 (-10.46% 1D, market cap $137.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NBP ranks #632 in composite RQD confidence.

How does NBP compare to RNA and MSLE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RNA (Atrium Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $141.5M) and MSLE (Satellos Bioscience Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $142.2M). Among the 5-stock peer group, NBP leads on earnings multiple (N/A) while MENS leads on capital efficiency (-28.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NBP?

Per NBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778016), NovaBridge Biosciences generated $264.0M in revenue (+83.3% YoY), -$46.3M in net income, and $0 in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NBP trading relative to its 50-day, 200-day, and 52-week technical levels?

NBP last traded at $1.07 (-10.46% on volume of 1,067,819 shares), positioning the stock -27.70% below its 50-day simple moving average ($1.48) and -50.46% below its 200-day simple moving average ($2.16). Across its 52-week range of $1.15 to $5.19, NBP sits at the 0.0% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.20).

Direct Sub-Reports: NBP RQD Cockpit NBP 12M Forecast NBP Earnings & Move NBP Dividends & DRIP NBP Insiders & 13F NBP Whale Options NBP Profit Sankey NBP News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

NBP — NovaBridge Biosciences: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NovaBridge Biosciences (NBP) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.07 (-10.46% 1D, market capitalization $137.9M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NovaBridge Biosciences is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. It has a market capitalization of $0.1B.6M in FY 2023 indicates minimal or no current commercial revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NovaBridge Biosciences (NBP) reported $264.0M in annual revenue (up from $144.0M in FY2024, +83.3% YoY) and -$46.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($632.0K revenue, -$207.7M net income) through FY2025, NBP scaled operating cash flow to $0 and free cash flow to $0, backed by $260.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.15 – $5.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is the Health Care / Biotechnology: Pharmaceutical Preparations classification and a beta of 1.0.

  • Key Question #1: Can NBP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $264.0M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NBP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NBP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NovaBridge Biosciences (NBP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NBP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NBP Bull vs. Bear Conversation Board — What's Your Call at $1.07?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NBP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NBP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.44 (+20.0%)
📌 Pinned Debate

Reported cash of $210.6M in FY 2025 exceeds the $139.6M market capitalization, and a GREEN-tagged exclusive-rights catalyst for VIS-102

Long NBP at $1.20 targeting $1.44. Reported cash of $210.6M in FY 2025 exceeds the $139.6M market capitalization, and a GREEN-tagged exclusive-rights catalyst for VIS-102 has been reported.. Institutional whale score is 3/20 and the risk/reward vs. the $1.15 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.20 and keeping dry powder in case we test $1.12.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.96 (-20.0%)
Spot @ $1.20

Valuation & margin reality check on NBP at $1.20 before chasing here

I respect the product at NovaBridge Biosciences, but the stock at $1.20 is a different story. Valuation & margin reality check on NBP at $1.20 before chasing here. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%